PHARMEXCIL Strengthens India-UAE Partnership

Hyderabad:  The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) has announced its renewed commitment to strengthening the strategic partnership between India and the United Arab Emirates (UAE) in the pharmaceutical sector.

Raja Bhanu, Director General of PHARMEXCIL along with the Advisor to Pharmexcil AVPS Chakravarthi recently had the privilege of meeting Aref Ali Alnuaimi, Consul General of the UAE, in Hyderabad. The meeting highlighted the enduring economic and commercial ties between the two nations, with a particular focus on pharmaceutical exports and collaboration in drug development, formulations, vaccines, and Active Pharmaceutical Ingredients (APIs).

As part of its efforts to enhance this collaboration, PHARMEXCIL is hosting the India Pavilion at Arab Health 2025, one of the most prestigious healthcare and pharmaceutical exhibitions in the region. Scheduled to take place from January 27-30, 2025, at the World Trade Center (WTC), Dubai to be inaugurated by Satish Kumar Siven, Consul General of India to UAE at Dubai on 27th January, 2025 This premier event will feature participation from 65 leading Indian pharmaceutical companies.

The India Pavilion will serve as a showcase for India’s excellence in pharmaceutical manufacturing and innovation, offering a platform for Indian companies to present their products and capabilities to global stakeholders, explore new business opportunities, and deepen engagement with the UAE market.

PHARMEXCIL invites stakeholders from across the healthcare industry to visit the India Pavilion and explore the vast potential of Indian pharmaceuticals.

SOURCE : BioSpectrum India

Related Posts

  • Pharma
  • February 17, 2025
  • 68 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 66 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%